<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doses and common adverse effects of medications used to treat suspected or confirmed MAC lymphadenitis in children and adolescents&lt;SUP&gt;[1-4]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doses and common adverse effects of medications used to treat suspected or confirmed MAC lymphadenitis in children and adolescents<sup>[1-4]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Doses and common adverse effects of medications used to treat suspected or confirmed MAC lymphadenitis in children and adolescents<sup>[1-4]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Route</td> <td class="subtitle1">Usual maximum daily dose</td> <td class="subtitle1">Potential adverse effects and target dose ranges</td> </tr> <tr class="divider_bottom"> <td>Azithromycin</td> <td> <ul> <li>5 to 10 mg/kg per day in 1 dose for daily dosing</li> <li>10 mg/kg per day in 1 dose for 3 times per week dosing</li> </ul> </td> <td>Oral</td> <td> <ul> <li>Daily: 300 mg/day</li> <li>3 times per week: 500 mg/day</li> </ul> </td> <td> <ul> <li>Prolongation of the QT interval; nausea; vomiting; diarrhea; decreased hearing; dizziness; hepatitis; phlebitis (IV)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Clarithromycin*</td> <td> <ul> <li>15 to 30 mg/kg per day divided in 2 doses (for daily or 3 times per week dosing)<sup>¶</sup></li> </ul> </td> <td>Oral</td> <td> <ul> <li>1 g/day</li> </ul> </td> <td> <ul> <li>Prolongation of the QT interval; nausea; vomiting; diarrhea; taste disturbance; decreased hearing; hepatitis<sup>Δ</sup> ; anterior uveitis<sup>Δ</sup> ; arthralgia<sup>Δ</sup> ; granulocytopenia<sup>Δ</sup> ; inhibits hepatic drug metabolism causing significant drug-drug interactions (particularly with rifamycins)</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Ethambutol*</td> <td> <ul> <li>15 mg/kg per day in 1 dose for daily dosing</li> <li>25 mg/kg per day in 1 dose for 3 times per week dosing<sup>Δ</sup></li> </ul> </td> <td>Oral</td> <td> <ul> <li>Daily: 1 g/day</li> <li>3 times per week: 2.5 g/day</li> </ul> </td> <td> <ul> <li>Optic neuritis (usually reversible)<sup>◊</sup>; red-green color blindness<sup>§</sup>; gastrointestinal disturbances; hypersensitivity</li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rifabutin*<sup>¥</sup></td> <td> <ul> <li>10 to 20 mg/kg per day in 1 dose (for daily or 3 times per week dosing)</li> </ul> </td> <td>Oral</td> <td> <ul> <li>300 mg/day</li> </ul> </td> <td> <ul> <li>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis<sup>Δ</sup>; "flu-like" syndrome; thrombocytopenia; renal failure; myalgia; arthralgia<sup>Δ</sup>; granulocytopenia<sup>Δ</sup>; anterior uveitis<sup>Δ</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Rifampin (rifampicin)<sup>¥</sup></td> <td> <ul> <li>15 to 20 mg/kg per day in 1 dose (for daily or 3 times per week dosing)</li> </ul> </td> <td>Oral</td> <td> <ul> <li>Children weighing &lt;50 kg: 450 mg/day</li> <li>Children weighing ≥50 kg: 600 mg/day</li> </ul> </td> <td> <ul> <li>Orange discoloration of secretions (may stain soft contact lenses), urine, and stool; gastrointestinal disturbance; hepatitis; "flu-like" syndrome; thrombocytopenia; renal failure; induces hepatic drug metabolism causing multiple significant drug-drug interactions</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Medications that may be added if <em>Mycobacterium tuberculosis</em> cannot be excluded</td> </tr> <tr class="divider_bottom"> <td class="indent1">Isoniazid</td> <td> <ul> <li>10 to 15<sup>‡</sup> mg/kg per day in 1 dose</li> </ul> </td> <td>Oral, IM</td> <td> <ul> <li>300 mg/day</li> </ul> </td> <td> <ul> <li>Mild hepatic enzyme elevation; hepatitis<sup>‡</sup>; peripheral neuritis; hypersensitivity (fever, rash); diarrhea and gastric irritation (caused by vehicle in syrup)</li> <li>Pyridoxine supplementation of 1 to 2 mg/kg per day (up to 50 mg/day) is suggested to prevent peripheral neuropathy in exclusively breastfed infants, children and adolescents on meat- and milk-deficient diets, children with nutritional deficiencies, children and adolescents with symptomatic HIV infection, and pregnant adolescents</li> </ul> </td> </tr> <tr> <td class="indent1">Pyrazinamide*</td> <td> <ul> <li>30 to 40 mg/kg per day for daily dosing</li> <li>50 mg/kg per day for twice weekly dosing</li> </ul> </td> <td>Oral</td> <td> <ul> <li>2 g/day</li> </ul> </td> <td> <ul> <li>Arthralgia; gastrointestinal</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Surgical excision without antimicrobial therapy is the preferred treatment for NTM lymphadenitis; antimycobacterial therapy is an alternative for children who are not candidates for surgery or patients/families who wish to avoid surgery. MAC is the most common cause of NTM lymphadenitis in the United States. If <em>M. tuberculosis</em> is not a concern, a typical empiric regimen for MAC lymphadenitis includes a macrolide (azithromycin or clarithromycin) in combination with ethambutol and/or rifampin (or rifabutin). Patients are typically treated until symptoms resolve (eg, 3 to 6 months). If <em>M. tuberculosis</em> is a concern, isoniazid (and possibly pyrazinamide) is added. Refer to UpToDate topic on NTM lymphadenitis in children for details.</div><div class="graphic_footnotes">MAC: <em>Mycobacterium avium</em> complex; IV: intravenous; IM: intramuscular; NTM: nontuberculous mycobacterial infection (also known as atypical mycobacterial infection).<br/>* Doses are for children with normal renal function.<br/>¶ Clinical data in adults indicate that 3 times weekly therapy is as effective as daily therapy, with reduced toxicity, for mild to moderate disease.<br/>Δ Anterior uveitis, arthralgia, neutropenia, and liver function abnormalities may occur when clarithromycin is used in combination with rifabutin.<br/>◊ Rare at doses of 15 to 25 mg/kg in children with normal renal function.<br/>§ Rarely occurs in children, who metabolize ethambutol more rapidly than adults.<br/>¥ Dose may require modification based upon drug-drug interactions, particularly with clarithromycin.<br/>‡ The incidence of hepatotoxicity may be increased when isoniazid doses &gt;10 mg/kg are used in combination with rifampin.</div><div class="graphic_reference">References: 

<ol>
<li>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</li>
<li>American Academy of Pediatrics. Tuberculosis. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.786.</li>
<li>Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: Literature review and recommendations. Int J Tuberc Lung Dis 2006; 10:1318.</li>
<li>Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</li></ol></div><div id="graphicVersion">Graphic 132531 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
